What's new

Orphan designation: Alrefimotide acetate,riletamotide acetate,tapderimotide acetate Treatment of mesothelioma, 21/03/2024 Withdrawn

Orphan designation: Alrefimotide acetate,riletamotide acetate,tapderimotide acetate Treatment of mesothelioma, 21/03/2024 Withdrawn

Apr 9, 2025 - 09:35
 0
Orphan designation: Alrefimotide acetate,riletamotide acetate,tapderimotide acetate Treatment of mesothelioma, 21/03/2024 Withdrawn
Orphan designation: Alrefimotide acetate,riletamotide acetate,tapderimotide acetate Treatment of mesothelioma, 21/03/2024 Withdrawn
Read More

Tags:

Previous Article

Orphan designation: Lactobacillus plantarum Treatment of amyotrophic lateral scl...

Next Article

US Prez Donald Trump triples tariffs on low-value imports from China

Related Posts

Decision of the European Medicines Agency on rules rela...

Mar 26, 2025  0

Call for scientific data for the periodic review of the...

Apr 1, 2025  0

Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, Date of authorisation: 16/11/2011, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025  0